BBA
XBIT icon

Baker Bros. Advisors’s XBiotech XBIT Stock Holding History

Baker Bros. Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-521,327
Closed -$5.45M – 105
2019
Q3 		$5.45M Buy
521,327
+140,885
+37% +$1.15M 0.04% 60
2019
Q2 		$2.88M Buy
+380,442
New +$3.31M 0.02% 75

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Baker Bros. Advisors's XBIT Position: Q4 2019 in Review

Baker Bros. Advisors sold out of XBiotech (XBIT) in Q4 2019, closing a stake of 521,327 shares — an estimated $5.45M sold.

Baker Bros. Advisors first reported a position in XBIT in Q2 2019 and held it in 2 quarters. The position peaked at $5.45M in Q3 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q4 2019.

  • Baker Bros. Advisors reported no remaining XBiotech position as of Q4 2019 after selling out during the quarter.
  • Baker Bros. Advisors sold 521,327 XBiotech shares in Q4 2019, an estimated $5.45M.
  • Baker Bros. Advisors first reported a position in XBiotech in Q2 2019 and held it in 2 quarters.
  • Baker Bros. Advisors's XBiotech position peaked at $5.45M in Q3 2019.
  • 60 funds tracked by Wall St. Rank held XBiotech as of Q4 2019.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.